Compare Mesoblast Limited (MESO) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs McCormick & Company, Incorporated — how do they compare? Mesoblast Limited trades at $14.25 (market cap $1.75B), while McCormick & Company, Incorporated trades at $44.94 (market cap $12.39B). The key difference: McCormick & Company, Incorporated is far larger — about 7.1× Mesoblast Limited's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and McCormick & Company, Incorporated for 67 Days on average.
| MESO | MKC | |
|---|---|---|
Market Cap | $1.75B | $12.39B |
Volume | 239,027 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $71.65 |
52-Week Low | $13.19 | $44.14 |
Typical Hold Time | 15 Days | 67 Days |
Enterprise Value | $1.83B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
MKC trades at $45.005, down 0.54% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, supported by the McCormick de Mexico acquisition. Valuation metrics appear attractive with a P/E of 8.31 and net income margin of 19.39%, while analyst consensus shows a mixed but predominantly hold rating.
The stock presents value opportunities with below-sector P/E ratios and consistent dividend payments, but faces technical headwinds and competitive pressures. Upside potential exists toward the $53.50 consensus target, though investors should monitor integration execution and consumer spending trends given the bearish technical indicators and mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
